Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment

Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ: LEXX) has announced a podcast titled “Hypertension: The Silent Killer Making Loud Noise for Investors.” The global anti-hypertensive drugs market is projected to grow from $24.37 billion in 2021 to $27.81 billion by 2025, highlighting a significant market opportunity. Lexaria's proprietary drug-delivery technology, DehydraTECH™, enhances the absorption of fat-soluble drugs and has applications across various product formats. With a market cap of around $35 million, Lexaria aims to capitalize on this growing sector and has a robust intellectual property portfolio with 21 patents granted.

Positive

• Significant market opportunity in the anti-hypertensive drugs sector, projected to reach $27.81 billion by 2025.
• Lexaria's DehydraTECH™ technology significantly enhances bioabsorption, with proven increases up to 10 times.
• Robust intellectual property portfolio with 21 patents granted, positioning Lexaria as a leader in drug delivery.

Negative

• None.

NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Hypertension: The Silent Killer Making Loud Noise for Investors.”

To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast

To view the full editorial, please visit: https://nnw.fm/ndmMU

The market is certainly worth entering. Consider that Reportlinker.com estimates the global anti-hypertensive drugs market to be $24.37 billion in 2021 and growing 3.4% annually to $27.81 billion in 2025. That’s a nearly $28 billion market where only one patient in four is treating the disease. How big would that market be if the other three in four patients found a drug they would consent to use?

Lexaria Bioscience Corp. (NASDAQ: LEXX) may have a market cap of only around $35 million, but it is an emerging technological leader pursuing more effective delivery systems for the potential treatment of hypertension. Lexaria has commercialized its unique and powerful drug-delivery technology, branded DehydraTECH(TM), which has been both laboratory and market proven to enhance the performance of several categories of fat-soluble active molecules and drugs, across oral and/or topical product formats.

About Lexaria Bioscience Corp.

Lexaria Bioscience’s proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption of cannabinoids and nicotine by up to 5 to 10 times, reduce time of onset from one to two hours to minutes, and mask unwanted tastes; the technology is planned to be further evaluated for orally administered bioactive molecules including anti-viral drugs, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide.

For more information about the company, please visit www.LexariaBioscience.com. 

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX 

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

FAQ

What is Lexaria Bioscience Corp.'s market cap?

Lexaria Bioscience Corp. has a market cap of approximately $35 million.

What is the projected growth of the global anti-hypertensive drugs market?

The global anti-hypertensive drugs market is expected to grow from $24.37 billion in 2021 to $27.81 billion by 2025.

What technology does Lexaria use for drug delivery?

Lexaria uses its proprietary DehydraTECH™ technology to enhance the absorption of fat-soluble drugs.

How many patents does Lexaria hold for its drug delivery technology?

Lexaria holds 21 patents granted and has more than 50 patents pending worldwide.